R&D Trends

AstraZeneca, MedImmune join chronic kidney disease consortium

Friday, February 12, 2016

AstraZeneca and its global biologics research and development arm MedImmune have entered into a collaboration with the University of Michigan and Eli Lilly to identify new therapeutic targets for the treatment of chronic kidney diseases (CKD). The RPC2 consortium (renal precompetitive consortium) will combine extensive clinical and molecular data collected by Professor Matthias Kretzler at the University of Michigan with the R&D expertise of the pharmaceutical industry.

[Read More]

Biogen joins Center for Therapeutic Target Validation

Wednesday, February 10, 2016

Biogen has joined the Center for Therapeutic Target Validation (CTTV), a public-private collaboration to improve the success rate for discovering new medicines. Originally formed by GlaxoSmithKline, the Wellcome Trust Sanger Institute and the European Bioinformatics Institute (EMBL-EBI), the CTTV fosters deep, ongoing interactions between academic and industry members for the purpose of developing open, transformative approaches to selecting and validating novel targets in drug development.

[Read More]

FDA seeks $5.1B for FY 2017

Wednesday, February 10, 2016

The FDA is requesting a total budget of $5.1 billion to protect and promote the public health as part of the President’s fiscal year (FY) 2017 budget—an 8% increase over the enacted budget for FY 2016. The overall request includes a net increase of $14.6 million in budget authority and $268.7 million in user fees for initiatives tied to several key areas, including the implementation of the FDA Food Safety Modernization Act (FMSA) and efforts to improve medical product safety and quality. The agency is also seeking $75 million in new mandatory funding to support the National Cancer Moonshot initiative being led by the vice president.

[Read More]

RCPCH launches a Children’s Health Research Capacity Development Fund

Tuesday, February 9, 2016

Substantial advances have been made over the last decade in preventing and treating disease, but discovery science and biomedical research, essential for the advancement of medicine, remain disproportionately focused upon adult conditions. This has prompted the Royal College of Pediatrics and Child Health (RCPCH) to launch a Children’s Health Research Capacity Development Fund to support a growth in the number of child health researchers in the U.K. and abroad.

[Read More]

EMA sets up task force on Zika virus

Tuesday, February 9, 2016

The EMA has established a task force of European experts with specialized knowledge in vaccines, infectious diseases and other relevant expertise to contribute to the global response to the threat of the Zika virus infection. This group will be available to give advice on any scientific and regulatory matters for the research and development of medicines or vaccines against the virus.

[Read More]

Bipartisan legislation introduced to combat Zika virus

Friday, February 5, 2016

U.S. Representatives G. K. Butterfield (NC-01) and Susan Brooks (IN-05) have introduced H.R. 4400, a bipartisan bill that seeks to add the Zika virus to the list of diseases included in the Tropical Disease Priority Review Voucher Program at the FDA. The Zika virus, which is transmitted to humans by mosquitoes, can infect pregnant women and result in birth defects, including microcephaly and neurological disorders in newborns. The virus also causes skin rashes, conjunctivitis, muscle and joint pain, and headaches in adults. The World Health Organization has labeled Zika a global public health emergency.

[Read More]